JP4596734B2 - スタチン副作用の処置 - Google Patents
スタチン副作用の処置 Download PDFInfo
- Publication number
- JP4596734B2 JP4596734B2 JP2002545692A JP2002545692A JP4596734B2 JP 4596734 B2 JP4596734 B2 JP 4596734B2 JP 2002545692 A JP2002545692 A JP 2002545692A JP 2002545692 A JP2002545692 A JP 2002545692A JP 4596734 B2 JP4596734 B2 JP 4596734B2
- Authority
- JP
- Japan
- Prior art keywords
- treatment
- composition
- uridine
- pain
- fatigue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Dental Preparations (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
本発明の1実施態様にしたがって、スタチン治療の1または2以上の副作用の処置の方法であって、そのような処置の必要な対象に、有効量のウリジン、その生物学的前駆体のいずれか、その塩、エステル、互変異性体または類似体を、有効量の式(I)
R1はHまたはC1−16アルキルであり、
R2およびR3はそれぞれ独立的に、H、ヒドロキシ、C1−16アルキル、C1−6アルコキシ、C1−6アルケニル、C1−6アルケンオキシ、C1−6アルキニルまたはC1−6アルキンオキシから選択され、そして
R4は、アルキル、アルケニル、アルコキシ、アルケンオキシ、アルキルオールまたはアルケニルオールである]
の少なくとも1つの化合物の投与と同時的に、逐次的にまたは別個に投与することを含む方法を提供する。
図1は、30日の期間にわたり定量された、Q10を服用する患者の筋肉疼痛の不存在の増加を図示する。
以下に続く本明細書および請求の範囲を通じて、文脈が特に要しない限り、用語「含む」および活用形、例えば「含む」および「含んでいる」は、言及されている整数または工程または整数の群の包含を意味するが、他の整数または工程または整数の群を除外することを意味しないと理解される。
(a)経口投与、外部適用(例えば水性および非水性溶液または懸濁液を含む水薬)、錠剤、丸薬、粉末、顆粒、食品との混合用の球粒、舌への適用のためのペースト;
(b)非経腸投与、例えば皮下、筋肉内、または滅菌溶液または懸濁液としての静脈内注射、
(c)局所適用、例えばクリーム、軟膏、ゲル、ローション等。
実施例1
白人男性の約54歳の患者は、長年、脚にはじまり他の骨格筋に徐々に広がる原因不明の筋肉疼痛に罹患していた。症状の最悪時に、患者はその腕を頭より上に持ち上げることができず、そして車を運転できなかった。歩行はまた困難であった。
白人女性の約44歳の患者は、長年、慢性疲労症候群に罹患していた。状態は彼女が職業の教職を遂行できなかったほど十分重症であり、そして毎日の仕事は全般に、一般的な意味の疲労および筋肉疼痛を有しつつ実施された。筋肉疼痛は全般に、500mgのパラセタモルおよび8mgのリン酸コデインを含む店頭販売(すなわち非処方)鎮痛剤を1日あたり2−4錠剤で制御された。
パイロット臨床試験−補酵素Q10の、スタチン誘導性疲労および筋肉疼痛に罹患する患者への投与
表2は、高コレステロール血症の処置のためスタチン治療を経験し、かつ種々のレベル筋肉疼痛および疲労に罹患していると報告していた、4人の患者(#1−#4と番号を付す)についてのデータを概説する。この試験は継続中であるが、以下の結果は、第−1週(WK(−1))から第+4週(WK(+4))までのこれら4人の患者の試験を追う。
パイロット臨床試験−補酵素Q10およびオロチン酸マグネシウムの、スタチン誘導性疲労および筋肉疼痛に罹患する患者への投与
表3は、高コレステロール血症の処置のためのスタチン治療を経験し、かつ、種々のレベルの筋肉疼痛および疲労に罹患していると報告していた4人の患者(#i−#ivと番号を付す)についてのデータを概説する。この試験は、継続中であるが、以下の結果は第−1週(WK(−1))ないし第+4週(WK(+4))のこれら4人の患者に関する試験を追う。
Claims (10)
- ヒトにおけるスタチン治療の筋肉疼痛および/または疲労である副作用の処置に使用するための組成物であって、有効量のウリジン、ウリジン一リン酸、ウリジン三リン酸、オロチン酸、ジヒドロオロチン酸、トロアセチルウリジン、およびN−カルバモイルアスパルテートまたはそれらの塩もしくは互変異性体および有効量の補酵素Q10を含む、組成物。
- 当該副作用が疲労である、請求項1の組成物。
- 当該副作用が筋肉疼痛である、請求項1の組成物。
- オロチン酸またはその塩もしくは互変異性体を含む、請求項1の組成物。
- オロチン酸の塩がオロチン酸マグネシウムである、請求項1の組成物。
- 少なくとも1個のスタチンをさらに含む、請求項1に記載の組成物。
- 少なくとも1個のスタチンがアトルバスタチン、シンバスタチン、プラバスタチン、ロバスタチン、セリバスタチンおよびフルバスタチンから選択される、請求項6に記載の組成物。
- スタチン治療の筋肉疼痛および/または疲労である副作用の処置に使用するための組成物であって、有効量のオロチン酸マグネシウムおよび有効量の補酵素Q10を、所望により薬学的に許容される添加剤の1以上と共に含む組成物。
- 当該副作用が疲労である、請求項8の組成物。
- 当該副作用が筋肉疼痛である、請求項8の組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPR1773A AUPR177300A0 (en) | 2000-11-29 | 2000-11-29 | Therapeutic methods |
PCT/AU2001/001545 WO2002043721A1 (en) | 2000-11-29 | 2001-11-29 | Treatment of statin side effects |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010151665A Division JP2010248230A (ja) | 2000-11-29 | 2010-07-02 | スタチン副作用の処置 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2004531468A JP2004531468A (ja) | 2004-10-14 |
JP2004531468A5 JP2004531468A5 (ja) | 2009-04-02 |
JP4596734B2 true JP4596734B2 (ja) | 2010-12-15 |
Family
ID=3825810
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002545692A Expired - Fee Related JP4596734B2 (ja) | 2000-11-29 | 2001-11-29 | スタチン副作用の処置 |
JP2010151665A Pending JP2010248230A (ja) | 2000-11-29 | 2010-07-02 | スタチン副作用の処置 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010151665A Pending JP2010248230A (ja) | 2000-11-29 | 2010-07-02 | スタチン副作用の処置 |
Country Status (11)
Country | Link |
---|---|
US (3) | US20040063661A1 (ja) |
EP (1) | EP1343488B1 (ja) |
JP (2) | JP4596734B2 (ja) |
AT (1) | ATE369845T1 (ja) |
AU (3) | AUPR177300A0 (ja) |
CA (1) | CA2429979C (ja) |
DE (1) | DE60130023T2 (ja) |
ES (1) | ES2292643T3 (ja) |
HK (1) | HK1059044A1 (ja) |
NZ (1) | NZ526069A (ja) |
WO (1) | WO2002043721A1 (ja) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPR951101A0 (en) * | 2001-12-13 | 2002-01-24 | Centre For Molecular Biology And Medicine | Method of treatment |
WO2004105742A1 (en) * | 2003-06-02 | 2004-12-09 | Isis Innovation Limited | Treatment of muscle fatigue |
WO2004108740A2 (en) | 2003-06-03 | 2004-12-16 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Nutritional supplements and therapeutic compositions comprising (r)-3-hydroxybutyrate derivatives |
CA2553690C (en) | 2004-01-22 | 2016-05-24 | Sung Lan Hsia | Topical co-enzyme q10 formulations and methods of use |
US20050288379A1 (en) * | 2004-06-21 | 2005-12-29 | Xiaoqiang Yan | Benzoquinone compounds as anti-cancer agents |
CA2571457A1 (en) * | 2004-06-21 | 2006-01-26 | Hutchison Medipharma Enterprises Limited | Cancer chemotherapy |
JP4896501B2 (ja) * | 2004-11-26 | 2012-03-14 | 第一三共株式会社 | 血中遊離脂肪酸低下作用を有する医薬組成物 |
WO2006057209A1 (ja) * | 2004-11-26 | 2006-06-01 | Sankyo Company, Limited | 血中遊離脂肪酸低下作用を有する医薬組成物 |
US20060252830A1 (en) * | 2005-05-06 | 2006-11-09 | Brandon Stephen F | Method for the treatment of magnesium and potassium deficiencies |
US20060252831A1 (en) * | 2005-05-06 | 2006-11-09 | Christopher Offen | Method for the treatment of magnesium and potassium deficiencies |
MX359292B (es) | 2005-06-01 | 2018-09-24 | Bioelectron Tech Corp | Sustancias terapeuticas activas redox para el tratamiento de enfermedades mitocondriales y otras condiciones y modulacion de biomarcadores de energia. |
WO2007095716A1 (en) * | 2006-02-23 | 2007-08-30 | Iomedix Sleep International Srl | Compositions and methods for the induction and maintenance of quality sleep |
WO2007127908A2 (en) * | 2006-04-28 | 2007-11-08 | Hutchison Medipharma Enterprises Limited | Dihydrobenzoquinone compounds |
EP2073819B1 (en) * | 2006-05-02 | 2016-12-28 | University of Miami | Topical co-enzyme q10 formulations and treatment of pain, fatigue and wounds |
TR201908522T4 (tr) | 2008-01-04 | 2019-07-22 | The Government Of The U S A As Represented By The Secretary Dept Of Health And Human Services | Kan lipidi düşürücü maddeler olarak keton gövdeleri ve keton gövde esterleri. |
JP5677856B2 (ja) | 2008-02-29 | 2015-02-25 | バイオラブ・サヌス・ファーマセウティカ・エルティーディーエー. | 医薬組成物 |
WO2009126764A1 (en) | 2008-04-11 | 2009-10-15 | Cytotech Labs, Llc | Methods and use of inducing apoptosis in cancer cells |
US8642654B2 (en) | 2009-04-16 | 2014-02-04 | Isis Innovation Limited | Hydroxybutyrate ester and medical use thereof |
LT3827815T (lt) | 2008-09-10 | 2023-10-10 | Ptc Therapeutics, Inc. | Psichologinių raidos sutrikimų gydymas oksidacijos redukcijos atžvilgiu aktyviais vaistais |
JP5426918B2 (ja) * | 2009-04-20 | 2014-02-26 | 株式会社 伊藤園 | ウリジンを含有する抗疲労剤又は体力向上剤 |
SG175993A1 (en) | 2009-05-11 | 2011-12-29 | Berg Biosystems Llc | Methods for treatment of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers |
US8557236B2 (en) * | 2010-02-09 | 2013-10-15 | Vascure Natural LLC | Cardiovascular support supplement and compositions and methods thereof |
GB201002983D0 (en) | 2010-02-22 | 2010-04-07 | Tdeltas Ltd | Nutritinal composition |
WO2012138765A1 (en) | 2011-04-04 | 2012-10-11 | Berg Pharma Llc | Methods of treating central nervous system tumors |
WO2013024425A1 (en) * | 2011-08-15 | 2013-02-21 | Technion Research And Development Foundation Ltd. | Combinations of corroles and statins |
TWI504390B (zh) * | 2012-09-18 | 2015-10-21 | Univ China Medical | 苯醌類化合物應用於抑制黑色素瘤細胞之Wnt/β-catenin訊息途徑之用途 |
TWI489982B (zh) * | 2012-09-18 | 2015-07-01 | Univ China Medical | 苯醌類化合物應用於抑制動脈粥狀血管硬化之用途 |
CA2922223C (en) | 2012-11-05 | 2021-11-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services And Human Services | Ketone bodies to protect tissues from damage by ionizing radiation |
GB201304467D0 (en) | 2013-03-12 | 2013-04-24 | Tdeltas Ltd | Compound for use in protecting skin |
JP6110959B2 (ja) | 2013-03-14 | 2017-04-05 | オックスフォード ユニヴァーシティ イノヴェーション リミテッド | (r)−3−ヒドロキシブチル(r)−3−ヒドロキシブチレートの製造方法 |
SG10201903112WA (en) | 2013-04-08 | 2019-05-30 | Berg Llc | Treatment of cancer using coenzyme q10 combination therapies |
WO2015003246A1 (en) * | 2013-07-09 | 2015-01-15 | Mcmaster University | Combination of a statin with an inflammasome inhibitor |
EA034143B1 (ru) | 2013-09-04 | 2020-01-09 | Берг Ллк | Способы лечения рака непрерывной инфузией кофермента q10 |
US10703701B2 (en) | 2015-12-17 | 2020-07-07 | Ptc Therapeutics, Inc. | Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
CN110769818A (zh) | 2017-05-17 | 2020-02-07 | 博格有限责任公司 | 辅酶q10制剂在治疗和预防大疱性表皮松解症中的用途 |
WO2018218287A1 (en) * | 2017-05-29 | 2018-12-06 | Woodlinda Pty Ltd | Treatment and/or prevention of neuropathic symptoms associated with diabetes mellitus type ii |
WO2019071353A1 (en) * | 2017-10-13 | 2019-04-18 | Exerkine Corporation | USE OF XC-SYSTEM INHIBITOR FOR THE TREATMENT OF STATIN-INDUCED MYALGIA |
KR102060722B1 (ko) * | 2017-11-06 | 2020-02-11 | 연세대학교 산학협력단 | 스타틴에 의한 약물유해반응용 동물 모델 및 이의 제조방법 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2462312A1 (de) * | 1974-03-04 | 1976-10-14 | Nadrol Chemie Pharma Keizer Kg | Arzneimittel zur behandlung von migraene-erkrankungen |
SU988814A1 (ru) * | 1979-11-20 | 1983-01-15 | Филиал Всесоюзного научно-исследовательского химико-фармацевтического института им.Серго Орджоникидзе | Соли оротовой кислоты и @ -аминокислот, предупреждающие развитие утомлени при физических нагрузках |
DE3110560A1 (de) * | 1981-03-18 | 1982-10-14 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen | "angiotropine der leukozyten und des entzuendungsgewebes: eine neue klasse natuerlicher chemotropischer mitogene fuer das richtungswachstum von blutgefaessen und zur neovaskularisierung von geweben" |
US4911917A (en) * | 1988-06-28 | 1990-03-27 | Hauser-Kuhrts, Inc. | Cholesterol-lowering combination comopsitions of magnesium salt and niacin |
US4929437A (en) * | 1989-02-02 | 1990-05-29 | Merck & Co., Inc. | Coenzyme Q10 with HMG-CoA reductase inhibitors |
DE69001146T2 (de) * | 1989-01-18 | 1993-10-07 | Merck & Co Inc | Koenzym Q10 mit HMG-COA-Reduktase-Inhibitoren. |
US5316765A (en) * | 1989-09-07 | 1994-05-31 | Karl Folkers Foundation For Biomedical And Clinical Research | Use of coenzyme Q10 in combination with HMG-CoA reductase inhibitor therapies |
WO1993016704A1 (en) * | 1992-02-24 | 1993-09-02 | East Carolina University | Method of inhibiting carcinogenesis by treatment with dehydroepiandrosterone and analogs thereof |
BE1005939A6 (fr) * | 1992-05-14 | 1994-03-15 | Pirmez Thierry Dr | Utilisation des sels de l'acide orotique comme tranporteurs preferentiels d'oligo-elements. |
AU666372B2 (en) * | 1992-05-28 | 1996-02-08 | Centre For Molecular Biology And Medicine | Therapeutic compositions |
AT405477B (de) * | 1996-04-03 | 1999-08-25 | Norbert Mag Fuchs | Kombinationspräparat |
US6472378B2 (en) * | 1998-08-31 | 2002-10-29 | Pro-Neuron, Inc. | Compositions and methods for treatment of mitochondrial diseases |
US6245800B1 (en) * | 1999-06-08 | 2001-06-12 | Sigma-Tau | Method of preventing or treating statin-induced toxic effects using L-carnitine or an alkanoyl L-carnitine |
IT1317008B1 (it) * | 2000-04-04 | 2003-05-26 | Sigma Tau Healthscience Spa | Integratore alimentare energizzante sulla muscolatura scheletrica eprotettivo sull'apparato cardiovascolare. |
US6420342B1 (en) * | 2000-05-08 | 2002-07-16 | N.V. Nutricia | Nutritional preparation comprising ribose and medical use thereof |
-
2000
- 2000-11-29 AU AUPR1773A patent/AUPR177300A0/en not_active Abandoned
-
2001
- 2001-11-29 NZ NZ526069A patent/NZ526069A/en not_active IP Right Cessation
- 2001-11-29 EP EP01998341A patent/EP1343488B1/en not_active Expired - Lifetime
- 2001-11-29 AT AT01998341T patent/ATE369845T1/de not_active IP Right Cessation
- 2001-11-29 DE DE60130023T patent/DE60130023T2/de not_active Expired - Lifetime
- 2001-11-29 AU AU2002223302A patent/AU2002223302B2/en not_active Ceased
- 2001-11-29 US US10/433,074 patent/US20040063661A1/en not_active Abandoned
- 2001-11-29 WO PCT/AU2001/001545 patent/WO2002043721A1/en active IP Right Grant
- 2001-11-29 ES ES01998341T patent/ES2292643T3/es not_active Expired - Lifetime
- 2001-11-29 CA CA2429979A patent/CA2429979C/en not_active Expired - Fee Related
- 2001-11-29 JP JP2002545692A patent/JP4596734B2/ja not_active Expired - Fee Related
- 2001-11-29 AU AU2330202A patent/AU2330202A/xx active Pending
-
2004
- 2004-03-16 HK HK04101929A patent/HK1059044A1/xx not_active IP Right Cessation
-
2010
- 2010-02-16 US US12/706,257 patent/US20100144665A1/en not_active Abandoned
- 2010-07-02 JP JP2010151665A patent/JP2010248230A/ja active Pending
- 2010-08-04 US US12/849,943 patent/US20100323981A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2429979C (en) | 2011-11-15 |
DE60130023T2 (de) | 2008-05-08 |
JP2004531468A (ja) | 2004-10-14 |
EP1343488A4 (en) | 2005-05-04 |
EP1343488A1 (en) | 2003-09-17 |
DE60130023D1 (de) | 2007-09-27 |
US20100144665A1 (en) | 2010-06-10 |
HK1059044A1 (en) | 2004-06-18 |
ATE369845T1 (de) | 2007-09-15 |
CA2429979A1 (en) | 2002-06-06 |
NZ526069A (en) | 2006-11-30 |
AUPR177300A0 (en) | 2000-12-21 |
US20100323981A1 (en) | 2010-12-23 |
US20040063661A1 (en) | 2004-04-01 |
EP1343488B1 (en) | 2007-08-15 |
AU2330202A (en) | 2002-06-11 |
WO2002043721A1 (en) | 2002-06-06 |
ES2292643T3 (es) | 2008-03-16 |
JP2010248230A (ja) | 2010-11-04 |
AU2002223302B2 (en) | 2006-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4596734B2 (ja) | スタチン副作用の処置 | |
AU2002223302A1 (en) | Treatment of statin side effects | |
JP6336914B2 (ja) | 脳卒中の治療のためのホルボールエステルの組成物および使用方法 | |
JP2004531468A5 (ja) | ||
US20070105954A1 (en) | Formulation containing a carboxylic acid or an ester thereof | |
JPH0369886B2 (ja) | ||
KR20040004652A (ko) | 조효소 q 및 에이코사펜타에노산(epa) | |
JPH02243623A (ja) | 脂肪酸による治療および組成物 | |
EP1089726A2 (en) | Composition comprising ss-hydroxy-ss-methylbutyric acid and at least one amino acid | |
AU2907500A (en) | Essential fatty acids in the prevention of cardiovascular events | |
JP4986321B2 (ja) | 炎症性状態処置のための方法および組成物 | |
WO1995017889A1 (fr) | Composition therapeutique utile pour traiter l'hyperparathyroidie d'un patient en dialyse artificielle | |
US4910224A (en) | Method of modifying the lipid structure and function of cell membranes and pharmaceutical compositions for use therein | |
TWI331920B (en) | Unit dosage form for relieving or treating constipation in human patients | |
CN101132789A (zh) | 具有降脂性能的化合物 | |
EP0087865A2 (en) | Pharmaceutical composition | |
JP2024526939A (ja) | 酸化的網膜疾患の進行を抑制する方法 | |
EP0238198A2 (en) | Method of modifying the lipid structure function and expression of cell membranes and pharmaceutical compositions for use therein | |
JP3816545B2 (ja) | 人工透析患者の皮膚そう痒症治療組成物及び副甲状腺機能亢進症治療組成物 | |
US20230398109A1 (en) | Use of pqq and derivative thereof | |
ES2425045T3 (es) | Acetil-L-carnitina para la prevención de la neuropatía diabética periférica dolorosa | |
JP2005516912A (ja) | ウリジン誘導体を用いるスタチンの副作用の処置 | |
CN118019529A (zh) | 抑制氧化性视网膜疾病进展的方法 | |
RU2484841C1 (ru) | Способ профилактики атеросклероза, основанный на подавлении атерогенной модификации липопротеидов | |
JP2000290178A (ja) | 抗腫瘍剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041028 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20041028 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080902 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081202 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081209 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20090213 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100302 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100702 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20100729 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100824 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100921 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131001 Year of fee payment: 3 |
|
LAPS | Cancellation because of no payment of annual fees |